AU2018243670B2 - Compositions and methods for targeting and killing ALPHA-V BETA-3-positive cancer stem cells (CSCs) and treating drug resistant cancers - Google Patents

Compositions and methods for targeting and killing ALPHA-V BETA-3-positive cancer stem cells (CSCs) and treating drug resistant cancers Download PDF

Info

Publication number
AU2018243670B2
AU2018243670B2 AU2018243670A AU2018243670A AU2018243670B2 AU 2018243670 B2 AU2018243670 B2 AU 2018243670B2 AU 2018243670 A AU2018243670 A AU 2018243670A AU 2018243670 A AU2018243670 A AU 2018243670A AU 2018243670 B2 AU2018243670 B2 AU 2018243670B2
Authority
AU
Australia
Prior art keywords
antibody
cells
tumor
cancer
avp3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018243670A
Other languages
English (en)
Other versions
AU2018243670A1 (en
Inventor
David Cheresh
Hiromi WETTERSTEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2018243670A1 publication Critical patent/AU2018243670A1/en
Application granted granted Critical
Publication of AU2018243670B2 publication Critical patent/AU2018243670B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018243670A 2017-03-31 2018-03-30 Compositions and methods for targeting and killing ALPHA-V BETA-3-positive cancer stem cells (CSCs) and treating drug resistant cancers Active AU2018243670B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762479768P 2017-03-31 2017-03-31
US62/479,768 2017-03-31
PCT/US2018/025470 WO2018183894A1 (en) 2017-03-31 2018-03-30 Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers

Publications (2)

Publication Number Publication Date
AU2018243670A1 AU2018243670A1 (en) 2019-10-31
AU2018243670B2 true AU2018243670B2 (en) 2025-05-01

Family

ID=63676868

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018243670A Active AU2018243670B2 (en) 2017-03-31 2018-03-30 Compositions and methods for targeting and killing ALPHA-V BETA-3-positive cancer stem cells (CSCs) and treating drug resistant cancers

Country Status (12)

Country Link
US (2) US20200109205A1 (enExample)
EP (2) EP4353318A3 (enExample)
JP (2) JP2020512978A (enExample)
KR (1) KR102630070B1 (enExample)
CN (1) CN110662559A (enExample)
AU (1) AU2018243670B2 (enExample)
BR (1) BR112019020451A2 (enExample)
CA (1) CA3058458A1 (enExample)
EA (1) EA201992326A1 (enExample)
IL (1) IL269746A (enExample)
MX (1) MX2019011717A (enExample)
WO (1) WO2018183894A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12383634B2 (en) 2019-07-24 2025-08-12 Korea Basic Science Institute Single domain antibody targeting αVβ3 integrin
WO2021026024A1 (en) * 2019-08-02 2021-02-11 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers
MX2022013207A (es) * 2020-04-23 2023-01-24 Alpha Beta Holdings Llc Metodos y composiciones para el tratamiento de cancer.
CN112626118B (zh) * 2020-11-12 2023-06-23 清华-伯克利深圳学院筹备办公室 细胞株及其应用
CN118284622A (zh) * 2021-09-30 2024-07-02 阿尔法贝塔控股有限责任公司 治疗癌症的组合物和方法
CN115960160B (zh) * 2021-10-12 2024-07-16 南京大学 活细胞膜整合素αvβ3聚糖的原位糖链延长方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
WO2003075957A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
US20060040325A1 (en) * 2004-08-16 2006-02-23 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity
WO2012167028A2 (en) * 2011-06-02 2012-12-06 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
WO2015068847A1 (ja) * 2013-11-11 2015-05-14 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
WO2016100858A1 (en) * 2014-12-18 2016-06-23 The Regents Of The University Of California Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6007839A (en) 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
RU2194528C2 (ru) * 1996-05-31 2002-12-20 Дзе Скриппс Рисерч Инститьют Способы и композиции, используемые для ингибирования ангиогенеза
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
CN1261791A (zh) 1997-07-02 2000-08-02 Sdg有限公司 诊断或治疗用途的靶向脂质体构建物
KR100704140B1 (ko) 1999-02-12 2007-04-09 더 스크립스 리서치 인스티튜트 혈관형성 억제제 및 항-종양 면역요법제를 포함하는, 종양 및 전이를 치료하기 위한 약제학적 조성물 및 이를 포함하는 키트
CN1561968A (zh) 1999-04-23 2005-01-12 三菱化学株式会社 与抗体和聚亚烷基二醇结合的脂质体
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7858117B2 (en) 2002-02-21 2010-12-28 Novosom Ag Amphoteric liposomes and their use
EP1547581A1 (en) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
CN1917859A (zh) 2003-12-24 2007-02-21 日本株式会社Ltt生物医药 载药纳米微粒及其制备方法以及含有该纳米微粒的非肠道给药用制剂
WO2005084710A2 (en) 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
WO2006014035A1 (en) 2004-08-06 2006-02-09 Biospectrum, Inc. Multiple layered liposome and preparation method thereof
SG163548A1 (en) * 2005-06-30 2010-08-30 Centocor Inc Methods and compositions with enhanced therapeutic activity
WO2007012191A1 (en) 2005-07-27 2007-02-01 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
US20080088046A1 (en) 2006-10-13 2008-04-17 Steffen Panzner Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
EP1959958A4 (en) * 2005-11-14 2010-07-14 Univ Southern California INTEGRIN-BINDING SMALL MOLECULES
US20080089928A1 (en) 2006-06-13 2008-04-17 Stavroula Sofou Liposome drug carriers with ph-sensitivity
US20110319335A1 (en) * 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
AU2014331118B2 (en) * 2013-10-01 2019-07-25 Medimmune Limited Methods of treating and diagnosing alpha-V-beta-6 overexpressing cancer
WO2021026024A1 (en) * 2019-08-02 2021-02-11 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
WO2003075957A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
US20060040325A1 (en) * 2004-08-16 2006-02-23 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity
WO2012167028A2 (en) * 2011-06-02 2012-12-06 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
WO2015068847A1 (ja) * 2013-11-11 2015-05-14 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
WO2016100858A1 (en) * 2014-12-18 2016-06-23 The Regents Of The University Of California Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Delbaldo, C. et al., 'Phase I and pharmacokinetic study of etaracizumab (Abegrin®), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors', Invest New Drugs, (2008), vol. 26. *
Kim, T. et al., 'Combined anti-angiogenic therapy against VEGF and integrin alphavbeta3 in an orthotopic model of ovarian cancer', Cancer Bio Ther. (2009-01-01), col. 8, no. 23, pages 2263-2272. *
Mulgrew, K. et al., 'Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin®', Mol Cancer Ther, (2006), vol. 5, no. 12, pages 3122-3129, doi:10.1158/1535-7163.MCT-06-0356. *
Wettersten, H. et al., 'Targeting integrin avp3-expressing cancer stem cells to manipulate tumor-associated macrophages', Cancer Research, (2017-07-01), vol. 77, Sup. 13, doi: 10.1158-7445.AM2017-3966. *

Also Published As

Publication number Publication date
EP4353318A3 (en) 2024-07-17
BR112019020451A2 (pt) 2020-04-28
JP2020512978A (ja) 2020-04-30
US20200109205A1 (en) 2020-04-09
CA3058458A1 (en) 2018-10-04
KR20190133205A (ko) 2019-12-02
US20240067733A1 (en) 2024-02-29
EA201992326A1 (ru) 2020-03-13
IL269746A (en) 2019-11-28
EP3600422A1 (en) 2020-02-05
JP2021095423A (ja) 2021-06-24
EP3600422A4 (en) 2021-01-13
AU2018243670A1 (en) 2019-10-31
WO2018183894A1 (en) 2018-10-04
KR102630070B1 (ko) 2024-01-26
MX2019011717A (es) 2019-12-16
EP3600422B1 (en) 2023-10-18
CN110662559A (zh) 2020-01-07
EP4353318A2 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
US20240067733A1 (en) Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers
ES2904880T3 (es) Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1
JP6526037B2 (ja) Ｉｌ−４ｒアンタゴニストを投与することによる皮膚感染を処置するための方法
US20210077625A1 (en) Ray tracing technique for wireless channel measurements
JPWO2020130125A1 (ja) 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
KR20190067235A (ko) Vista 및 pd-1 경로의 이중 억제제
EP2951205B1 (en) Anti-activin-a compounds for the treatment of ovarian cancer
EP2882454B1 (en) Combination therapy for the treatment of glioblastoma
JP2014132009A5 (enExample)
JP2012500180A5 (enExample)
JP2017165786A (ja) 血管漏出症候群および癌を治療する方法
TW202108165A (zh) 治療癌症之方法
TW201024310A (en) Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
KR20100043242A (ko) 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약
KR20120104491A (ko) 암 치료를 위한 실렌기티드의 연속 투여
US11052089B2 (en) Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype
CN117015377A (zh) 使用波生坦与检查点抑制剂组合的癌症治疗
HK40110133A (en) Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers
CN114144181A (zh) 用于靶向和杀死α-vβ-3（αvβ3）阳性癌症干细胞（CSC）以及治疗耐药性和转移性癌症的组合物和方法
EP2262494A2 (en) Inhibition of post-radiation tumor growth by an inhibitor of vasculogenesis
BR122024020789A2 (pt) Composições e métodos para se direcionar e matar células-tronco positivas de câncer alfa-v beta-3 positiva (cscs) e tratamento de cânceres resistentes ao medicamento
EP2968539A1 (en) Combination/adjuvant therapy for wt-1-positive disease
Han Mechano-Responsive Immune Cell System for Cancer Metastasis
JP2025500789A (ja) チェックポイント阻害剤と組み合わせてケトチフェンを使用するがんの処置
EA048934B1 (ru) Способы лечения рака

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)